Application of biomaterials in treating early osteonecrosis of the femoral head: Research progress and future perspectives

Quan, Hongyu; Ren, Chencan; He, Yuwei; Wang, Fuyou; Dong, Shiwu; Jiang, Hong

doi:10.1016/j.actbio.2023.04.005

Cited by 13 publications

(3 citation statements)

References 132 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Excessive secretion of PDGF-BB by osteoclast precursors induces the formation of the CD31 hi Emcn hi vascular isoform (Figure 2), and the number of CD31 hi Emcn hi vessels increases significantly in OA. Moreover, vascularassociated osteoclasts (VAOs), a subtype of osteoclasts, can assist H-type blood vessels in eliminating cartilage [83][84][85][86]. Moreover, excessive angiogenesis promotes osteogenesis.…”

Section: The Role Of Subchondral Osteoclasts In Oamentioning

confidence: 99%

Subchondral osteoclasts and osteoarthritis: new insights and potential therapeutic avenues

Chen,

Wang,

Tao

et al. 2024

ABBS

View full text Add to dashboard Cite

Osteoarthritis (OA) is the most common joint disease, and good therapeutic results are often difficult to obtain due to its complex pathogenesis and diverse causative factors. After decades of research and exploration of OA, it has been progressively found that subchondral bone is essential for its pathogenesis, and pathological changes in subchondral bone can be observed even before cartilage lesions develop. Osteoclasts, the main cells regulating bone resorption, play a crucial role in the pathogenesis of subchondral bone. Subchondral osteoclasts regulate the homeostasis of subchondral bone through the secretion of degradative enzymes, immunomodulation, and cell signaling pathways. In OA, osteoclasts are overactivated by autophagy, ncRNAs, and Rankl/Rank/OPG signaling pathways. Excessive bone resorption disrupts the balance of bone remodeling, leading to increased subchondral bone loss, decreased bone mineral density and consequent structural damage to articular cartilage and joint pain. With increased understanding of bone biology and targeted therapies, researchers have found that the activity and function of subchondral osteoclasts are affected by multiple pathways. In this review, we summarize the roles and mechanisms of subchondral osteoclasts in OA, enumerate the latest advances in subchondral osteoclast-targeted therapy for OA, and look forward to the future trends of subchondral osteoclast-targeted therapies in clinical applications to fill the gaps in the current knowledge of OA treatment and to develop new therapeutic strategies.

show abstract

Section: The Role Of Subchondral Osteoclasts In Oamentioning

confidence: 99%

Subchondral osteoclasts and osteoarthritis: new insights and potential therapeutic avenues

Chen,

Wang,

Tao

et al. 2024

ABBS

View full text Add to dashboard Cite

show abstract

“…Usually, a bone tissue engineering approach consists of harvesting bone marrow from the iliac crest, abdominal fat, or other tissues, expanding those cells in vitro to a sufficient number, and then seeding the cells onto a suitable scaffold before implantation into the same patient for differentiation and/or tissue regeneration [15]. This approach allows the creation of an environment that drives and stimulates the cells to form new functional tissue that subsequently integrates into the existing tissue at the defect site [16,17]. The ability of MSCs to differentiate into various mesodermal cells, such as bone and cartilage lineages, and their immunomodulatory and anti-inflammatory capacities are widely acknowledged [18,19].…”

Section: Introductionmentioning

confidence: 99%

Bone Regeneration Using Mesenchymal Stromal Cells and Biocompatible Scaffolds: A Concise Review of the Current Clinical Trials

Borsani

Rezzani

et al. 2023

Gels

View full text Add to dashboard Cite

Bone regenerative medicine is a clinical approach combining live osteoblast progenitors, such as mesenchymal stromal cells (MSCs), with a biocompatible scaffold that can integrate into host bone tissue and restore its structural integrity. Over the last few years, many tissue engineering strategies have been developed and thoroughly investigated; however, limited approaches have been translated to clinical application. Consequently, the development and clinical validation of regenerative approaches remain a centerpiece of investigational efforts towards the clinical translation of advanced bioengineered scaffolds. The aim of this review was to identify the latest clinical trials related to the use of scaffolds with or without MSCs to regenerate bone defects. A revision of the literature was performed in PubMed, Embase, and Clinicaltrials.gov from 2018 up to 2023. Nine clinical trials were analyzed according to the inclusion criteria: six presented in the literature and three reported in Clinicaltrials.gov. Data were extracted covering background trial information. Six of the clinical trials added cells to scaffolds, while three used scaffolds alone. The majority of scaffolds were composed of calcium phosphate ceramic alone, such as β-tricalcium phosphate (TCP) (two clinical trials), biphasic calcium phosphate bioceramic granules (three clinical trials), and anorganic bovine bone (two clinical trials), while bone marrow was the primary source of the MSCs (five clinical trials). The MSC expansion was performed in GMP facilities, using human platelet lysate (PL) as a supplement without osteogenic factors. Only one trial reported minor adverse events. Overall, these findings highlight the importance and efficacy of cell–scaffold constructs in regenerative medicine under different conditions. Despite the encouraging clinical results obtained, further studies are needed to assess their clinical efficacy in treating bone diseases to optimize their application.

show abstract

“…In different countries, the annual incidence of ONFH is about 1.5-3.0 per 100,000 of the population [9]. The age of ONFH patients is mostly 30-50 years old [10,11].…”

Section: Introductionmentioning

confidence: 99%

Insight into Steroid-Induced ONFH: The Molecular Mechanism and Function of Epigenetic Modification in Mesenchymal Stem Cells

Huang,

Qing,

Xiao

et al. 2023

Biomolecules

View full text Add to dashboard Cite

Osteonecrosis of the femoral head (ONFH) is a common refractory orthopedic disease, which is one of the common causes of hip pain and dysfunction. ONFH has a very high disability rate, which is associated with a heavy burden to patients, families, and society. The pathogenesis of ONFH is not completely clear. At present, it is believed that it mainly includes coagulation dysfunction, abnormal lipid metabolism, an imbalance of osteogenic/adipogenic differentiation, and poor vascularization repair. The prevention and treatment of ONFH has always been a great challenge for clinical orthopedic surgeons. However, recent studies have emphasized that the use of mesenchymal stem cells (MSCs) to treat steroid-induced ONFH (SONFH) is a promising therapy. This review focuses on the role and molecular mechanism of epigenetic regulation in the progress of MSCs in the treatment of SONFH, and discusses the significance of the latest research in the treatment of SONFH from the perspective of epigenetics.

show abstract

Application of biomaterials in treating early osteonecrosis of the femoral head: Research progress and future perspectives

Cited by 13 publications

References 132 publications

Subchondral osteoclasts and osteoarthritis: new insights and potential therapeutic avenues

Subchondral osteoclasts and osteoarthritis: new insights and potential therapeutic avenues

Bone Regeneration Using Mesenchymal Stromal Cells and Biocompatible Scaffolds: A Concise Review of the Current Clinical Trials

Insight into Steroid-Induced ONFH: The Molecular Mechanism and Function of Epigenetic Modification in Mesenchymal Stem Cells

Contact Info

Product

Resources

About